Enanta Pharmaceuticals appoints new board member
Dr. Russell will also serve as a member of Enanta’s audit committee and its nominating and corporate governance committee, effective as of January 1, 2017.
Dr. Russell has over two decades of clinical, regulatory and drug development expertise.
Dr. Russell currently serves as Chief Medical Officer at Innocoll Holdings.
She held executive management positions at TetraLogic Pharmaceuticals, where she held the role of Chief Operating Officer from 2013 through 2016, and at Teva Pharmaceuticals, where she was Senior Vice president and Global Head of Research and Development from 2011-2012.
At Teva, Dr. Russell led a team of over 1,500 and was responsible for all aspects of global drug development. She spent over 10 years at Cephalon where she held positions of increasing responsibility from 2000 -2011, most recently serving as Executive Vice President and Chief Medical Officer.
Dr. Russell currently serves on the Boards of Directors of AMAG Pharmaceuticals, Endocyte Pharmaceuticals and Melmark.
Dr. Russell received a MB.Ch.B. degree from the University of Edinburgh, Scotland, Faculty of Medicine. She is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK. ■
LATEST MOVES FROM Massachusetts
- Pegasystems appoints Matt Cushing as vice president
- Akcea Therapeutics appoints three to board
- Silicon Therapeutics appoints Woody Sherman as CSO
- Dunkin' Brands Group CFO Paul Carbone to leave
- Abpro appoints Gavin MacBeath as CSO
More inside POST
Seadrill Q4 revenue $667 million Earnings